Abstract Details

Title Plasma Nerve Growth Factor Is Independent of Vitamin D Status in Subjects at Risk of Cognitive Decline

Topic Aging and Dementia

Presentation(s) P04 - (-)

Poster/Presentation
Number 228

Objective

Background BACKGROUND: The presence of vitamin D receptors throughout the nervous system raises the possibility that vitamin D has direct effects on the nervous system. Animal studies have shown that vitamin D administration results in an increase in NGF expression. If this mechanism operates in human subjects at typical vitamin D levels, then a correlation between plasma vitamin D and plasma NGF would be expected.

Design/Methods DESIGN/METHODS: Subjects included 19 older subjects with Mild Cognitive Impairment and 19 age-matched healthy controls. Each subject had plasma sampled at two timepoints spaced one month apart. Plasma NGF was measured by a commercial ELISA kit and plasma vitamin D3 was measured by HPLC.

Results RESULTS: The two groups were matched in age (75±1.7 in controls; 73±1.7 in MCI), but differed in gender (32% male in control; 68% male in MCI) and ApoE carrier status (26% carriers in control; 42% carriers in MCI). Vitamin D levels were detectable in all plasma samples and did not distinguish the two groups at either time point (30±2 ng/ml in controls and 28±2 ng/ml in MCI at each timepoint). In contrast, NGF was detectable in only 8 of 19 MCI and in 3 of 19 control subjects at each timepoint. Both vitamin D (R2=0.92; p<0.0001) and NGF (R2=0.971; p<0.0001) were reproducible within individuals. There were no significant correlations between plasma vitamin D and NGF, and no difference in plasma vitamin D between individuals with detectable and undetectable plasma NGF.

Conclusions CONCLUSIONS: The hypothesis that vitamin D status regulates NGF expression in human subjects is not supported by these findings.

Authors/Disclosures
Joseph F. Quinn, MD, FAAN (OHSU Neurology) PRESENTER	Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Disease Cooperative Study. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Therapeutic Research Institute. Dr. Quinn has a non-compensated relationship as a consultant with Cognition Therapeutics that is relevant to AAN interests or activities.
	No disclosure on file
Gene L. Bowman, ND (Harvard Medical School, Massachusetts General Brigham)	No disclosure on file
	No disclosure on file
Randall L. Woltjer (Oregon Health & Science University)	Randall L. Woltjer has nothing to disclose.
Jeffrey A. Kaye, MD, FAAN (Oregon Hlth Sci Univ.)	Dr. Kaye has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Kaye has stock in Life Analytics. The institution of Dr. Kaye has received research support from NIH. The institution of Dr. Kaye has received research support from NSF. The institution of Dr. Kaye has received research support from AbbVie. Dr. Kaye has received intellectual property interests from a discovery or technology relating to health care.
Amie L. Hiller, MD	The institution of Dr. Hiller has received research support from Admas Pharmaceuticals.

��ɫ��

��ɫ��